Literature DB >> 21821856

Characteristics and long-term outcome of echocardiographic super-responders to cardiac resynchronisation therapy: 'real world' experience from a single tertiary care centre.

Jan Steffel1, Gligor Milosevic, Anja Hürlimann, Nazmi Krasniqi, Mehdi Namdar, Frank Ruschitzka, Thomas F Lüscher, Firat Duru, Johannes Holzmeister, David Hürlimann.   

Abstract

BACKGROUND: The individual benefit from cardiac resynchronisation therapy (CRT) varies largely among patients. AIMS: To compare different definitions of echocardiographic super-response to CRT regarding their ability to predict the incidence of adverse events.
METHODS: Three definitions of super-response to CRT were evaluated in 110 consecutive patients with CRT implantation: (1) an absolute increase in ejection fraction of ≥ 10%; (2) a decrease in left ventricular end-systolic volume of ≥ 30%; and (3) a decrease in left ventricular end-diastolic volume of ≥ 20%. The primary endpoint was a combination of time to death, heart transplantation, ventricular assist device implantation and hospitalisation for heart failure. Secondary endpoints included time to first appropriate implantable cardioverter defibrillator (ICD) discharge during follow-up.
RESULTS: All three definitions of super-response were highly predictive of a reduced risk for reaching the primary combined endpoint (3-year estimators: 64% ± 7% vs 82% ± 7% for ejection fraction ≥ 10%; 63% ± 8% vs 92% ± 5% for end-systolic volume ≥ 30%; and 62% ± 8% vs 94% ± 4% for end-diastolic volume ≥ 20%; all p<0.001). In all three analyses, super-responders had a significantly shorter time from diagnosis of heart failure until the time point of CRT implantation. However, even super-responders, independent of the definition, did experience appropriate ICD discharges during follow-up.
CONCLUSIONS: All three definitions of super-response are highly predictive for a favourable outcome after CRT. However, even patients with pronounced reverse left ventricular remodelling experience appropriate ICD discharges during follow-up.

Entities:  

Mesh:

Year:  2011        PMID: 21821856     DOI: 10.1136/heartjnl-2011-300222

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  17 in total

1.  [Device therapy of chronic heart failure: Update 2015].

Authors:  C W Israel; L Ekosso-Ejangue; M-K Sheta
Journal:  Herz       Date:  2015-12       Impact factor: 1.443

2.  Effects of cardiac resynchronization therapy on left ventricular remodeling and dyssynchrony in patients with left ventricular noncompaction and heart failure.

Authors:  Qiong Qiu; Yang-xin Chen; Jing-ting Mai; Wo-liang Yuan; Yu-lin Wei; Ying-mei Liu; Li Yang; Jing-Feng Wang
Journal:  Int J Cardiovasc Imaging       Date:  2014-11-13       Impact factor: 2.357

3.  Cardiac resynchronization therapy update: evolving indications, expanding benefit?

Authors:  C Butcher; Y Mareev; V Markides; M Mason; T Wong; J G F Cleland
Journal:  Curr Cardiol Rep       Date:  2015-10       Impact factor: 2.931

4.  Outcome of super-responders to cardiac resynchronization therapy defined by endpoint-derived parameters of left ventricular remodeling: a two-center retrospective study.

Authors:  David Hürlimann; Susann Schmidt; Burkhardt Seifert; Ardan M Saguner; Gerhard Hindricks; Thomas F Lüscher; Frank Ruschitzka; Jan Steffel
Journal:  Clin Res Cardiol       Date:  2014-10-10       Impact factor: 5.460

Review 5.  When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion?

Authors:  Sana M Al-Khatib; Daniel J Friedman; Gillian D Sanders
Journal:  Card Electrophysiol Clin       Date:  2018-03

6.  Cardiac Resynchronisation Therapy and Heart Failure: Persepctive from 5P Medicine.

Authors:  Fang Fang; Zhou Yu Jie; Luo Xiu Xia; Liu Ming; Ma Zhan; Gan Shu Fen; Yu Cheuk-Man
Journal:  Card Fail Rev       Date:  2015-04

Review 7.  Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review.

Authors:  Neal A Chatterjee; Attila Roka; Steven A Lubitz; Michael R Gold; Claude Daubert; Cecilia Linde; Jan Steffel; Jagmeet P Singh; Theofanie Mela
Journal:  Eur Heart J       Date:  2015-08-10       Impact factor: 29.983

8.  Cardiac resynchronization therapy is associated with a reduction in ICD therapies as it improves ventricular function.

Authors:  Enrique Galve; Gerard Oristrell; Gabriel Acosta; Aida Ribera-Solé; Àngel Moya-Mitjans; Ignacio Ferreira-González; Jordi Pérez-Rodon; David García-Dorado
Journal:  Clin Cardiol       Date:  2018-06-05       Impact factor: 2.882

9.  Long-term outcome of patients with and without super-response to CRT-D.

Authors:  Jennifer Franke; Jeannette Keppler; Alamara Karimi Abadei; Amer Bajrovic; Lillian Meme; Christian Zugck; Philip W Raake; Edgar Zitron; Hugo A Katus; Lutz Frankenstein
Journal:  Clin Res Cardiol       Date:  2015-10-23       Impact factor: 5.460

10.  Improvement of left ventricular function under cardiac resynchronization therapy goes along with a reduced incidence of ventricular arrhythmia.

Authors:  Christian Eickholt; Marcus Siekiera; Kiriakos Kirmanoglou; Astrid Rodenbeck; Nicole Heussen; Patrick Schauerte; Artur Lichtenberg; Jan Balzer; Tienush Rassaf; Stefan Perings; Malte Kelm; Dong-In Shin; Christian Meyer
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.